Profil
Andrew King is currently Chief Scientific Officer at Jade Biosciences, Inc. (United States) since 2024 and President-Research & Development at Jade Biosciences, Inc. starting in 2026.
Former positions include Chief Scientific Officer at Chinook Therapeutics, Inc. from 2021 to 2023, and Senior Director-Discovery & Translational Biology at Ardelyx, Inc. Education includes a doctorate from Michigan State University and an undergraduate degree from Murdoch University.
Aktiva positioner av Andrew King
| Företag | Position | Start |
|---|---|---|
| JADE BIOSCIENCES, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2025-04-28 |
Tidigare kända positioner av Andrew King
| Företag | Position | Slut |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2023-08-09 |
| ARDELYX, INC. | Företagsledare/Principal | - |
Andrew Kings utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 5 |
|---|---|
Michigan State University
Michigan State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Murdoch University
Murdoch University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ardelyx, Inc.
Ardelyx, Inc. Pharmaceuticals: MajorHealth Technology Discovers and Develops therapeutic therapeutic drugs that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases | Health Technology |
Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes medicines for kidney diseases | Health Technology |
















